MetaVia Inc. (NASDAQ:MTVA – Free Report) – Equities research analysts at HC Wainwright issued their FY2029 EPS estimates for MetaVia in a research report issued on Friday, March 21st. HC Wainwright analyst E. Arce expects that the company will post earnings per share of ($5.01) for the year. HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for MetaVia’s current full-year earnings is ($3.90) per share.
MetaVia Price Performance
NASDAQ:MTVA opened at $1.58 on Monday. MetaVia has a 52-week low of $1.29 and a 52-week high of $5.30. The stock’s fifty day moving average price is $1.69.
MetaVia Company Profile
MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.
Featured Stories
- Five stocks we like better than MetaVia
- What is the Dow Jones Industrial Average (DJIA)?
- Super Micro Stock: $7.2M Call Options Signal Big Upside Potential
- Top Stocks Investing in 5G Technology
- Top 3 Buy-and-Hold Stocks for 2025: Long-Term Winners to Watch
- How to find penny stocks to invest and trade
- D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst?
Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.
